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Prostaglandin endoperoxide synthase (PGHS) catalyses the rate-
limiting step in the formation of prostaglandin and thromboxane
eicosanoids from arachidonic acid released by phospholipase A
#
.
Two forms of PGHS exist, PGHS-1 and PGHS-2. PGHS-2,
normally absent from cells, is rapidly expressed in response to a
wide variety of stimuli and has been implicated in the patho-
genesis of colon cancer and several inflammatory diseases. The
three principal mitogen-activated protein kinase (MAPK) path-
ways are the extracellular signal-regulated protein kinase (ERK),
the c-Jun N-terminal kinase (JNK) cascade and the p38-MAPK
cascade. The present study was undertaken to investigate the
putative involvement of the MAPK cascades in PGHS-2 in-
duction. The potential role of ERK in PGHS-2 up-regulation
was assessed by using cell lines expressing, both stably and after
adenoviral infection, constitutively active forms of its upstream
activator MAPK}ERK kinase (MEK1). The possible involve-
ment of JNK and p38-MAPK in positively modulating PGHS-
INTRODUCTION
Prostaglandin endoperoxide synthase (PGHS) is the enzyme that
catalyses the first, rate-limiting step in the formation of prosta-
glandins from arachidonic acid released by phospholipase A
#
[1].
Two forms of PGHS have been characterized, PGHS-1 and
PGHS-2. PGHS-2, normally absent from cells, is rapidly ex-
pressed in response to a wide variety of stimuli [1]. Expression of
PGHS-2 is elevated in colonic tumours [2–4] ; genetic evidence
has been provided that PGHS-2 expression is causal in the
development of colon polyps and carcinoma [5]. In addition,
PGHS-2 has been implicated in both the promotion [6] and
resolution [7] of inflammation.
It has been reported that the HCT-116 cancer cell line both
expresses elevated levels of PGHS-2 in the basal condition and
also has the capacity to drive the expression of a PGHS-2-
promoter–luciferase construct [8]. This result lends support to
the hypothesis that elevated PGHS-2 expression in colonic cancer
might be due to dysregulated transcription and would suggest
that a transcription factor aberrantly over-activated (or over-
expressed) in carcinoma cells facilitates the abnormal expression
Abbreviations used: C/EBP, CCAAT-enhancer-binding protein ; CRE, cAMP-response element ; ERK, extracellular signal-regulated protein kinase ;
FBS, fetal bovine serum ; HUVEC, human umbilical-vein endothelial cells ; JNK, c-Jun N-terminal kinase ; MAPK, mitogen-activated protein kinase ; MEK,
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virus 40 ; tHMC, SV40-transformed human mesangial cells.
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2 transcription was investigated by using adenovirus-mediated
transfer of active forms of their respective specific upstream
kinases, mitogen-activated protein kinase kinase (MKK) 7 and
MKK3}MKK6. ERK activation promoted the induction of
PGHS-2 mRNA and protein. Similarly, activation of JNK by
Ad-MKK7D and p38-MAPK by Ad-MKK3bE}Ad-MKK6bE
resulted in the increased expression of PGHS-2. These results
provide evidence that activation of all three of the major
mammalian MAPK leads to the induction of PGHS-2 mRNA
and protein. Because PGHS-2 is up-regulated by a diverse range
of stimuli, both mitogenic and stress-evoking, these results
provide evidence that the convergence point of these stimuli
could be the activation of one or more MAPK cascade(s).
Key words: colon cancer, inflammation, signal transduction,
transcriptional up-regulation.
of PGHS-2. Alternatively, a negative regulator of PGHS-2
transcription might be lost or non-functional in these cells. The
promoter}enhancer region of the various mammalian PGHS-2
genes share a number of modulatory elements, including cAMP-
response element (CRE), nuclear factor (NF)-IL6, NF-jB and
activator protein 2 [9]. The first three of these consensus sequences
have been implicated in ligand-dependent up-regulation of the
human enzyme [9–12] ; in addition it has been proposed that p53
might negatively regulate PGHS-2 expression by binding to
the TATA sequence (located between fi13 and fi26 bp in the
human gene) [13].
The three principal mitogen-activated protein kinase (MAPK)
pathways are the extracellular signal-regulated protein kinase
(ERK), the c-Jun N-terminal kinase (JNK) and the p38-MAPK
cascades [14]. These cascades consist of a three-kinase module
composed of the tertiary kinase or MAPK (ERK, JNK and p38-
MAPK), activated by a MAPK}ERK kinase (MEK, also referred
to as MAPK kinase or MKK), which in turn is activated by a
MEK kinase (MEKK). ERK is activated by MEK, which is
activated by Raf, the prototypic mammalian MEKK. JNK
is activated by MKK4 and MKK7, and p38-MAPK by MKK4,
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MKK3 and MKK6 [14–20]. In addition, evidence exists that
MKK3, MKK4, MKK6 and MKK7 can be activated by
MEKK1–3 [14,16]. The ERK pathway is mobilized by a wide
range of extracellular stimuli, including G-protein-coupled
ligands, growth factors and cytokines ; activation of this pathway
is integral to the signalling of agents evoking cellular proliferation
and differentiation. The stress-activated MAPK, JNK and p38-
MAPK have been shown to have pivotal roles in cellular response
to both extracellular and intracellular stress ; in contrast with
ERK, their activation generally promotes growth inhibition and
induces apoptosis [14].
ERK, JNK and p38-MAPK are activated by many of the
diverse stimuli capable of inducing PGHS-2 expression [14].
Moreover, the regions of the human PGHS-2 proximal promoter
that have been shown to be involved in mediating the up-
regulation of this enzyme bind a number of MAPK-activated
transcription factors [9,14]. In the current study we therefore
investigated the ability of the three principal MAPKs to
drive PGHS-2 up-regulation. The putative role of ERK in
mediating PGHS-2 transcription was studied by using cell lines
expressing constitutively active forms of its upstream activator
MEK1 (also known as MKK1) [14]. The possible modulation of
PGHS-2 expression by JNK and p38-MAPK was investigated by
means of adenovirus-mediated transfer of constitutively active
MKK7 [15–18] and MKK3}MKK6 [19,20] constructs.
EXPERIMENTAL
Materials
All cell culture reagents and routine biochemicals were obtained
from Sigma Chemical Co. (St Louis, MO, U.S.A.). Anti-MEK
and anti-(phospho-MAPK) [anti-(phospho-JNK) and anti-
(phospho-p38-MAPK)] antibodies were from New England
Biolabs (Beverly, MA, U.S.A.). Anti-(PGHS-2) antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.).
Enhanced chemiluminescence (ECL2) kits were obtained from
Amersham (Piscataway, NJ, U.S.A.). Protein determinations
were performed by means of a bicinchoninic acid assay obtained
from Pierce (Rockford, IL, U.S.A.). A plasmid containing a full-
length 4.2 kb PGHS-2 insert was kindly provided by Dr Harvey
Herschman (Los Angeles, CA, U.S.A.). The MEK1 constructs
used in adenoviral generation and NIH 3T3 cells expressing
MEK1 constructs were kindly provided by Dr Nathalie Ahn
(Boulder, CO, U.S.A.).
Stable cell lines
Parental NIH 3T3 fibroblasts and stably transfected cell lines
derived from these were propagated in Dulbecco’s modified
Eagle’s essential high-glucose medium, supplemented with 10%
(v}v) heat-inactivated calf serum, 100 i.u.}ml penicillin and
100 lg}ml streptomycin. Cell lines expressing the pSV2neo vector
or pMM9 vector constructs encoding constitutively active MEK1
(DN3}S222D; deletion of a predicted a-helix encompassing
residues 32–51 and replacement of the regulatory Ser-222 residue
with Asp), wild-type MEK1 and catalytically inactive MEK1
(K97M) under the control of the Maloney sarcoma virus long
terminal repeat are as described previously [21]. Cells were made
quiescent for 24 h before experiments.
Recombinant adenoviral vectors
A second catalytically active MEK1 construct (DN3}S218E-
S222D, achieved by the replacement of both regulatory residues,
Ser-218 and Ser-222, with glutamic and aspartic residues re-
spectively and the deletion of a predicted a-helix encompassing






the replication-deficient adenovirus type 5 (Ad5) with deletions
in the E1 and E3 genes (Ad-d1327), and a plasmid containing
Ad5 sequences from bp 22 to bp 5790 with a deletion of the E1
region from bp 342 to bp 3523, a polycloning site under the
control of the CMV promoter, the mutated human MEK1 gene
and the simian virus 40 (SV40) polyadenylation signal [22]. The
recombinant adenoviral constructs encoding activated MKK6
(Ad-MKK6bE), MKK3 (Ad-MKK3bE) and MKK7 (Ad-
MKK7D) have been described previously [23–25].
Adenoviral infection
Human umbilical-vein endothelial cells (HUVEC) were cultured
in MCDB 105 medium containing 20% (v}v) fetal bovine serum
(FBS) and endothelial cell growth supplement (80 lg}ml).
HUVEC were rendered quiescent overnight in MCDB medium
containing 1% (v}v) FBS. Cells were infected with Ad-MEK
CA
and the non-transgenic control virus Ad-d1327 at a multiplicity
of infection (MOI) of 60, essentially as described previously [22].
The adenovirus-mediated gene transfer of MEK1 was verified by
Western blot analysis of cell lysates with anti-MEK antibodies
and the concomitant activation of ERK by means of an
immunocomplex assay. At various time points after infection,
total RNA was isolated and Northern analysis for PGHS-2
mRNA was performed.
For experiments with Ad-MKK7D and Ad-MKK3bE}
MKK6bE, SV40-transformed human mesangial cells (tHMC)
[22,26] were rendered quiescent for 24 h before being infected
with Ad-MKK7D at a MOI of 100, with Ad-MKK3bE}
MKK6bE at a MOI of 50}50 or with a control adenovirus
encoding b-galactosidase (Ad-LacZ) at a MOI of 100, as de-
scribed previously [22]. After 36 h the cells were lysed and the
resultant cell lysates were subjected to a Western blot analysis
with phospho-specific anti-JNK and anti-(p38-MAPK) anti-
bodies. Having thus confirmed adenoviral transfer and the
consequent activation of JNK and p38-MAPK, Western blot
analysis of PGHS-2 expression was performed.
RNA extraction and Northern blot analysis
Total cellular RNA was isolated by the acid guanidinium
thiocyanate method [27] and analysed exactly as described
elsewhere [28].
Western analysis and immunocomplex assays
Western blot analysis and MAPK immunocomplex assays were
performed exactly as described previously [29]. For ERK assays,
samples standardized for protein (400 ll, prepared as described
above) were immunoprecipitated with a polyclonal antibody
against p42 ERK [29]. After incubation with Protein A–
Sepharose, samples were washed twice with lysis buffer and twice
with kinase assay buffer (20 mM Hepes, pH 7.4, containing
10 mM MgCl
#
and 200 lM orthovanadate) before being resus-
pended in 60 ll of kinase buffer containing 0.25 mg}ml myelin
basic protein, 50 lM ATP and 5 lCi of [c-$#P]ATP. The reaction
was initiated by incubation at 30 °C for 15 min and terminated
by the addition of 60 ll of Laemmli buffer. The samples were
then subjected to SDS}PAGE [12% (w}v) gel], followed by
autoradiographic development.
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RESULTS AND DISCUSSION
Activation of each of the three major MAPK cascades (ERK,
JNK and p38-MAPK) results in the mobilization of numerous
transcription factors and the up-regulation of target genes [14].
Here we present results that support the hypothesis that the
induction of PGHS-2 expression in response to a variety of
stimuli might be secondary to the activation of one or more
of the three major MAPK cascades.
Investigations employing pharmacological MEK inhibitors
have provided evidence that the ERK pathway is involved in
PGHS-2 induction [30,31]. In addition, it has been reported that
the overexpression of both wild-type ERK-1 and ERK-2 poten-
tiates v-Src-mediated activation of a murine PGHS-2 promoter
construct and have speculated that that this might occur in an
Figure 1 Fibroblasts transfected with the constitutively active MEK1
mutant demonstrate an increased level of PGHS-2 protein
pSVneo-transfected cells are shown unstimulated and after stimulation with endothelin-1 (ET-
1 ; 100 nM, for 22 h). Quiescent cells stably expressing constitutively active MEK1 (DN3/S222D)
demonstrated PGHS-2 expression at a level comparable to that induced in mock-transfected
cells by ET-1. Shown is a representative experiment ; the experiment was performed at least
three times.
Figure 2 HUVEC infected with Ad-MEKCA exhibit increased MEK protein expression, ERK activation, induction of PGHS-2 mRNA and PGHS-2 protein
expression
Cell lysates of HUVEC infected with adenovirus encoding constitutively active MEK (N3/S218E-S222D) for 6 h (Ad-MEKCA) or control cells (uninfected) were subjected to SDS/PAGE and Western
blot analysis with anti-MEK antibodies (left-hand top panel). Lysates were subjected to a confirmatory immunocomplex assay for ERK activity (left-hand middle panel). As a positive control, uninfected
cells were stimulated with 20% (v/v) FBS for 5 min (uninfected, 20% FBS). The positions of MEK1 and MBP (myelin basic protein) are indicated. Expression of PGHS-2 in these cell lysates was
determined by Western analysis with anti-(PGHS-2) antiserum (left-hand bottom panel). At the various time points shown after the infection of HUVEC with AdMEKCA or control Ad-DL327 (lanes
corresponding to cells that received no adenovirus are indicated as uninfected), total cellular RNA was isolated and Northern blot analysis was performed with PGHS-2 cDNA (right-hand upper
panel). After stripping of the membrane, it was rehybridized with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe to confirm even loading of RNA (right-hand lower panel).
Elk-1-dependent manner [32]. The putative role of ERK in
PGHS-2 induction was assessed in the current study by using
both cell lines stably transfected, and primary cells adenovirally
infected, with constitutively active MEK1 constructs. The NIH
3T3 DN3}S222D cell line is invaluable for studying the down-
stream targets of ERK activation because this MAPK pathway
is continuously activated in these cells, independently of extra-
cellular stimuli. Cells stably expressing MEK DN3}S222D exhibit
greatly enhanced basal ERK activity when compared with cells
transfected with vector only (pSV2neo) or cells expressing wild-
type or catalytically inactive (K97M) MEK1 ([21], and results
not shown). Correspondingly, levels of PGHS-2 protein [as
assessed by probing cell lysates normalized with regard to protein
with anti-(PGHS-2) antiserum] in quiescent NIH 3T3 DN3}
S222D cells were found to be elevated in comparison with cells
transfected with vector only (pSV2neo) or cells expressing wild-
type or catalytically inactive MEK1 (Figure 1). DN3}S222D 3T3
cells also demonstrated constitutive up-regulation of PGHS-2
mRNA (results not shown); however, to determine the time
course of PGHS-2 mRNA induction in response to ERK
activation, an adenoviral construct encoding a second catalyti-
cally active MEK1 mutant, DN3}S218E-S222D, was employed
and this, together with a control adenovirus construct, was used
to infect HUVEC. Adenovirus-mediated MEK1 expression was
confirmed by Western analysis (Figure 2, left-hand top panel)
and the activation of ERK in cells infected with Ad-MEK
CA
was
verified by immunocomplex assay (Figure 2, left-hand middle
panel). In agreement with the results obtained from the DN3}
S222D fibroblast cell line, adenovirus-mediated constitutively
active MEK1 expression also led to increased PGHS-2 protein
expression (Figure 2, left-hand bottom panel). Northern analysis
with a full-length PGHS-2 cDNA probe revealed that, in
comparison with control virus-infected HUVEC, cells transfected
with Ad-MEK
CA
exhibited an induction of PGHS-2 mRNA
within 3 h of infection; this was increased at 6 and 9 h (Figure 2,
right-hand panel).
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Figure 3 Stress-activated MAPK activation and PGHS-2 expression are
increased after infection of tHMC with Ad-MKK3bE/Ad-MKK6bE and Ad-
MKK7D
Cell lysates of tHMC infected with Ad-LacZ, Ad-MKK3bE/Ad-MKK6bE or Ad-MKK7D for 36 h
were subjected to SDS/PAGE and Western blot analysis with anti-(PGHS-2) antibodies (top
panel), anti-(phospho-JNK) antibodies (middle panel) or anti-(phospho-p38-MAPK) antibodies
(lower panel). The positions of PGHS-2, phospho-JNK and phospho-p38-MAPK are indicated.
Shown is a representative experiment ; the experiment was repeated twice with similar results.
These results indicate that the sustained activation of ERK by
two distinct catalytically active MEK1 mutants results in the up-
regulation of PGHS-2 in both fibroblasts and HUVEC; taken
together, the results support a role for activated ERK in the
transcriptional up-regulation of PGHS-2. In addition to Elk-1,
ERK has also been reported to phosphorylate and activate NF-
IL6 [also known as CCAAT-enhancer-binding protein (C}EBP)
b] [33]. Although the consensus motif for this transcription
factor has been shown to be involved in the induction of
human PGHS-2, this seems to be mediated via the binding
of C}EBPd [10]. NF-IL6 has been shown to regulate c-Fos ex-
pression [34] and thus, like Elk-1, might well have a role in the
potentiation of PGHS-2 expression. The present results provide
novel evidence in itro that activated ERK is capable of not only
potentiating [32] but actually effecting PGHS-2 transcription.
To assess the putative involvement of the stress-activated
MAPK in the modulation of PGHS-2 expression, adenoviral
constructs encoding constitutively active variants of their re-
spective specific activating kinases were employed. MKK7 has
been demonstrated to be a specific activator of the JNK family
kinases [15–18], whereas p38-MAPK is the principal target of
MKK3 and MKK6 [19,20]. tHMC were infected with equal
adenoviral titres of Ad-MKK7D or a combination of Ad-
MKK3bE and Ad-MKK6bE. Although Ad-MKK3bE and
Ad-MKK6bE can each activate p38-MAPK independently, by
using a combination of the two adenoviral constructs the possi-
bility of isoform-specific activation of p38-MAPK by one or other
of these MKKs is overcome [24]. Successful adenoviral transfer
and activity were confirmed by means of Western blot analysis of
phosphorylated, and hence activated, JNK and p38-MAPK by
using phospho-specific antibodies (Figure 3). As can be seen,
infection with Ad-MKK7D led to a marked activation of both
the p46 and p54 JNK isoforms but had virtually no effect on the
activation status of p38-MAPK (Figure 3, middle and bottom
panels). Similarly, infection with Ad-MKK3bE}Ad-MKK6bE
resulted in a significant activation of p38-MAPK without having
any effect on either JNK isoform (Figure 3, middle and bottom
panels). Cells transduced with Ad-LacZ exhibited no activation
of either JNK or p38-MAPK (Figure 3, middle and bottom
panels) and none of the three adenoviral constructs was found to
activate ERK (results not shown).
Having thus confirmed the substrate specificity of the adeno-
viral constructs, the expression of PGHS-2 in tHMC cell lysates
was also assessed by Western blotting. Infection of tHMC with
either Ad-MKK7D or an Ad-MKK3bE}Ad-MKK6bE com-
bination (with the consequent constitutive activation of JNK
and p38-MAPK respectively) led to a marked increase in the
expression of PGHS-2, whereas infection with Ad-LacZ had no
effect on PGHS-2 protein levels (Figure 3, top panel). These
results confirm that both stress-activated MAPKs are capable of
driving PGHS-2 transcription. It has been reported that MEKK-
1-dependent JNK activation results in the activation of a murine
PGHS-2 promoter construct [32,35]. Guan et al. [36] reported
that activation of the MEKK-1}MKK4 module up-regulates
PGHS-2 expression via the concomitant activation of JNK and
p38-MAPK; interestingly, they also found that the over-
expression of a constitutively active MEKK-1 mutant resulted in
the activation of MKK4 but not MKK3 or MKK6. Significantly,
in the present study, novel evidence is given that the stress-
activated MAPKs can each independently drive PGHS-2 expres-
sion and that this occurs in a MKK7-dependent and MKK3}
6-dependent manner.
JNKphosphorylates c-Jun on itsN-terminal activating domain
[37], thereby inducing the formation of c-Jun homodimers and c-
Jun–c-Fos heterodimers and leading to up-regulated transcrip-
tion activity of numerous genes via activator protein 1 and CRE
sites [38,39]. Studies have indicated that the CRE site of human
PGHS-2 is involved in C}EBP-mediated up-regulation [10] and
it has been reported that this site also facilitates the c-Jun-driven
transcription of human and murine PGHS-2 [32,35,40]. Similarly,
although p38-MAPK has been reported to activate a number of
transcription factors [14] and to be involved in PGHS-2 up-
regulation [36], the precise mechanism by which this MAPK
facilitates PGHS-2 expression is as yet undetermined.
With regard to the potential role of MAPK cascades in
effecting constitutive PGHS-2 expression in colonic cancer, ERK
activation has been paralleled with tumorigenic progression in
rat intestinal neoplasia [41] and it has been reported that
pharmacological MEK inhibition significantly suppresses colonic
tumour growth in itro and in io [42]. In contrast, Wang and
co-workers concluded that the ERK1}2 activity was down-
regulated in colorectal tumour in comparison with adjacent
normal tissue [43], and other investigators have correlated
decreased ERK expression and activity with the progression of
normal gastric tissue to adenoma [44,45]. Although our own
investigations have confirmed tumour-associated PGHS-2 ex-
pression, we did not detect enhanced ERK activation in human
colon cancer samples in comparison with control tissue (results
not shown). In addition, although tumour tissue from five of
eight patients exhibiting neoplasia-associated PGHS-2 had in-
creased levels of JNK activity, and p38-MAPK displayed a
tentative trend towards tumour-associated phosphorylation
(results not shown), these results were far from unequivocal.
Although JNK activation has been paralleled with tumorigenic
progression in rat intestinal neoplasia [41], Wang and co-workers
have reported that the activities of both JNK1 and p38-MAPK
were in fact down-regulated in colorectal tumours in comparison
with normal tissue [43]. It therefore seems that the role of ERK,
JNK and p38-MAPK in the pathogenesis of colon cancer is still
unclear and that, by extrapolation, so too does the involvement
of these MAPKs in driving tumour-associated PGHS-2 expres-
sion.
In conclusion, the findings of the present study provide
evidence that MAPK cascades are the convergence point of the
numerous diverse stimuli that have been reported to up-regulate
PGHS-2. However, although the ligand-dependent activation of
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one or more of these cascades might drive pathogenic expression
of PGHS-2 in, for example, inflammatory models [46], the role of
MAPK in mediating colon-cancer-associated expression of this
enzyme remains to be established.
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